+391.7%
APP vs MRNA
-8.5%
+400.1%
-91.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +2.2% | -2.2% | +4.5% | +2.4% |
| 7D | +0.9% | +5.5% | -4.6% | +0.4% |
| 30D | -23.3% | +158.7% | -182.0% | -35.5% |
| 3M | -42.6% | +182.1% | -224.8% | -53.0% |
| 6M | -33.6% | +151.8% | -185.4% | -44.7% |
| YTD | -52.4% | +393.6% | -446.0% | -65.6% |
| 1Y | -35.9% | +499.5% | -535.3% | -56.0% |
| 3Y | +642.2% | +29.3% | +612.9% | +556.6% |
| 5Y | +311.1% | -65.1% | +376.2% | +315.7% |
| All | +391.7% | -8.5% | +400.1% | +284.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling